Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping ...

In a significant stride for chronic disease management, FDA granted approvals for Roche’s lupus nephritis treatment and Novo Nordisk’s cardiovascular-risk-reducing oral semaglutide for adults with ...

An April 2025 report from the Initiative for Medicines, Access & Knowledge (I-MAK) presents grossly misleading information ...

Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...

WeightWatchers said on Monday it will partner with Amazon to deliver medications including injectable GLP-1 obesity ...

Pfizer ( PFE) is number one and the leader in my list of "top 3 Big Pharma stocks." Over the last three quarters I have seen ...

In what some news reports dubbed " an awkward moment ," CMS Administrator Mehmet Oz, MD, stepped up to the podium in the Oval Office last week to correct President Donald Trump on the status of GLP-1 ...

WeightWatchers Clinic can now get weight loss medications though Amazon Pharmacy (NASDAQ:AMZN), capitalizing on the ...

Semaglutide 7 mg and 14 mg tablets are now available for reducing the risk of cardiovascular death, heart attack, or stroke ...

WW International shares rise nearly 6% after announcing a partnership with Amazon Pharmacy to deliver GLP-1 weight-loss drugs directly to customers.